The FDA recently designated Yuflyma as "interchangeable" with the popular biologic Humira for the treatment of Crohn's disease and ulcerative colitis, two types of inflammatory bowel disease (IBD), ...
AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...
AbbVie ABBV is a dominant player in the immunology space, powered by three blockbuster drugs — Skyrizi, Rinvoq and Humira — which together account for nearly half of its top line. Although the company ...
AbbVie ABBV delivered encouraging second-quarter 2025 results last week, sending a clear message — it is effectively managing its post-Humira transition. The stronger-than-expected sales of newer ...
Zacks.com on MSN
Here's What We Expect From AbbVie's Immunology Segment in Q4
ABBV's Q4 outlook hinges on surging Skyrizi and Rinvoq demand, as investors watch immunology sales to offset Humira's past ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback